High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer.
Chingunjav BatbayarNorihiro IshiiNorifumi HarimotoTakehiko YokoboriHideyuki SaitoDolgormaa GantumurNavchaa GombodorjBilguun Erkhem-OchirRyo MuranushiKouki HoshinoTakahiro YamanakaKei HagiwaraMariko TsukagoshiAkira WatanabeKenichiro ArakiYasuo HosouchiKen ShirabePublished in: International journal of clinical oncology (2023)
High levels of RRN3 expression are associated with poor prognosis and cancer malignancy, such as proliferation, invasion ability, and chemosensitivity in pancreatic cancer. RRN3 targeting with anticancer drugs may be a promising therapeutic strategy to overcome refractory pancreatic cancer.